A protocol for targeted B-lymphocyte depletion for the treatment of IgG4-related disease
Rituximab administration targeting B-cell depletion for a two-year period is an effective treatment strategy for IgG4-RD and can limit the cumulative glucocorticoid exposure. Flares are uncommon and typically occur in the setting of B-cell repopulation, with good clinical responses to further rituximab administration.
Authors
- Florian Wernig (ORCID: https://orcid.org/0000-0001-5914-9318)
- Eva Bolton (ORCID: https://orcid.org/0000-0002-1191-0849)
- Constantinos A. Parisinos (ORCID: https://orcid.org/0000-0003-1844-9263)
- Tara Barwick (ORCID: https://orcid.org/0000-0002-9776-8766)
- Matthew Colquhoun
- Frederick WK Tam
- Jeremy Levy (ORCID: https://orcid.org/0000-0001-7498-6413)
- Natalie Philips
- Stephen P. McAdoo (ORCID: https://orcid.org/0000-0001-8260-8770)
- Archie Hughes‐Hallett (ORCID: https://orcid.org/0000-0003-1595-1805)
- Taryn Youngstein (ORCID: https://orcid.org/0000-0002-8297-556X)
- James S. Tomlinson (ORCID: https://orcid.org/0000-0001-8299-8211)
- Norma Gibbons
Institutions
- Imperial College Healthcare NHS Trust (GB)
- Hammersmith Hospital (GB)
- Chelsea and Westminster Hospital (GB)
- Imperial College London (GB)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2024-12-11
- DOI
- https://doi.org/10.1093/rheumatology/keae675
- Citations
- 7
- Primary Topic
- IgG4-Related and Inflammatory Diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.29
Funders
- Pfizer
- AstraZeneca
- National Institute for Health and Care Research
- National Institutes of Health
- NIHR Imperial Biomedical Research Centre